PARP inhibition in Prostate Cancer: Optimizing Care for Veterans

Get up to date on optimal Veterans Affairs care of patients receiving combination and single-agent PARP inhibitor regimens for prostate cancer with downloadable slides, an on-demand webcast, and expert commentary.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.

AstraZeneca

Merck & Co., Inc., Rahway, NJ, USA